Release date: 2015-04-08
With the development of biotechnology, scientists have developed more and more new methods to fight cancer. In addition to tumor immunotherapy, which has become so popular in recent years, tumor gene therapy has also been recognized by more and more scientists.
However, because this therapy directly affects the genetic material in patients, many researchers are still cautious about this therapy. At the same time, based on the experience of tumor gene therapy in the past few years, this method does have such problems as compared with immunotherapy. Therefore, few heavyweight tumor gene therapy studies have been reported in recent years.
However, the recent biopharmaceutical company MultiVir from Houston decided to continue to take a big step forward. The company has formally submitted a $70 million IPO plan to the Securities and Exchange Commission to support the company's development of viral vector technology into the second phase of the clinical phase. This time, MultiVir plans to introduce an adenoviral vector treatment for colon cancer and head and neck cancer. If all goes well, MultiVir is expected to be the first gene therapy to be approved for FDA approval.
MultiVir also highlighted the research features of the two gene therapies the company is currently working on in the relevant application materials. First, in order to dispel market concerns, the two adenoviral recombinant vectors developed by the company will not integrate host cell DNA to reduce the risk of side effects. The company emphasizes that the side effects of gene therapy for tumors do not exceed existing chemotherapy, radiotherapy, and immunotherapy. The side effects of the drugs mentioned in the company's documents include allergies, fatigue, fever and other symptoms.
In addition, the company will also incorporate recombinant viral vectors into the lesion site in conjunction with different drug delivery systems. The researchers will use the intravenous injection of adenoviral vector drug Ad-p53 to treat colon cancer, and the intratumoral injection of the drug Ad-IL-24 for the treatment of head and neck tumors.
However, it is interesting to note that in this report MultiVir also specifically mentioned the Chinese company Sebino Gene. MultiVir claims that a gene therapy sold by Cybino is similar to Ad-p53 and infringes on some of MultiVir's patents.
Source: Bio Valley
total alkalinity: prevent fluctuation in pH levels
Free Chlorine: Chlorine may be present in tap water. It is harmful to fish, damaging their gills and skin, and must not be introduced to the aquarium
pH: pH value between 6.5 and 8.5 will be tolerated by most freshwater fish species
Bromine: Keep your bromine levels on point and effective
Total hardness: prevent corrosion and scaling in your pool or spa
tatal chlorine: know exactly when to shock your water
Spa Test Kits,Hard Water Tester,Best Digital Pool Test Kit,Swimming Pool Test Strips
Changchun LYZ Technology Co., Ltd , https://www.lyzstrips.com